Wockhardt (WOCKPHARMA) Q2 25/26 earnings summary

Executive summary

• Consolidated revenue for Q2 FY26 was ₹803 crore, down from ₹818 crore in Q2 FY25; H1 FY26 revenue was ₹1,561 crore versus ₹1,587 crore in H1 FY25.

• Net profit after tax for Q2 FY26 was ₹82 crore, compared to a loss of ₹16 crore in Q2 FY25; H1 FY26 net loss was ₹26 crore versus a loss of ₹32 crore in H1 FY25.

• Exceptional item of ₹97 crore due to deconsolidation and impairment from exit of US generic business, impacting H1 FY26 results.

Financial highlights

• Standalone revenue for Q2 FY26 was ₹410 crore, up from ₹381 crore in Q2 FY25; H1 FY26 revenue was ₹848 crore versus ₹759 crore in H1 FY25.

• Standalone net profit after tax for Q2 FY26 was ₹54 crore, compared to a loss of ₹36 crore in Q2 FY25; H1 FY26 net profit was ₹123 crore versus a loss of ₹30 crore in H1 FY25.

• Consolidated EBITDA improved due to cost control and operational efficiencies.

• Basic and diluted EPS for Q2 FY26 were ₹4.81, compared to negative ₹1.47 in Q2 FY25.

Outlook and guidance

• The group has exited the US generic pharmaceutical business, focusing on core markets and operational efficiency.

• Management expects improved profitability from the streamlined business structure.